Bernard-Soulier syndrome have been analyzed by surface-labeling coupled with two-dimensional gel electrophoresis and compared with normals. As well as the previously described absence or deficiency in glycoprotein (GP) Ib(a) it could be shown that GP Ib,3 and an additional low molecular weight glycoprotein GP75.8-65 were not detectable using carbohydrate-labeling methods or deficient to the same extent as the GPIba subunit. In addition, the thrombin cleavable glycoprotein could not be detected using carbohydrate-labeling methods in two patients and was deficient in a third. This finding was confirmed in a fourth patient by one-dimensional gel electrophoresis. Thus, the changes in the membrane of Bernard-Soulier platelets are more complex than previously thought.
INTRODUCTION
Bernard-Soulier syndrome is an inherited bleeding disorder characterized by reduced adherence of the platelets to subendothelium (1), the presence of "giant" platelets in blood smears (2) and a reduced platelet survival time in circulation (3) resulting in thrombocytopenia. Bernard-Soulier platelets aggregate nor-FVIIIR:WF (5) or bovine von Willebrand factor (4) . Aggregation to, and binding of, thrombin is reduced compared to normal platelets (6, 7) .
Biochemical studies on Bernard-Soulier platelets first showed a reduction in sialic acid content (3) and later a deficiency in the membrane glycoprotein lb was demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with (8) or without (9) surface-labeling of platelets and has been confirmed in several additional studies (10) (11) (12) (13) including crossed immunoelectrophoresis (14) . Glycocalicin, a readily solubilized platelet glycoprotein derived from glycoprotein Ib was also shown to be decreased in BernardSoulier syndrome (10, 11) . Unlike Glanzmann's thrombasthenia, another platelet disorder, involving principally glycoproteins Ilb and Illa, where considerable heterogeneity has been reported (14) , little is known about heterogeneity and its relation to clinical symptoms in Bernard-Soulier syndrome, due largely to the rareness of this disorder. It has not yet been established if the genetically determined abnormality of the membrane of BernardSoulier platelets is restricted to glycoprotein lb or if other membrane components are affected. A report has appeared that there are changes in glycosylation in Bernard-Soulier platelets compared with normal (15) . Glycoprotein lb consists of two subunits, a and , linked by at least one disulphide bond (16) . Since previous studies had been carried out on relatively low concentration polyacrylamide gels in order to examine the major glycoproteins, nothing was known about the expression of the 13-subunit in Bernard-Soulier syndrome.
To examine the question of heterogeneity in Bernard-Soulier syndrome and to see if glycoprotein lb is the only glycoprotein affected in this disorder, we have surface-labeled Bernard-Soulier platelets and analyzed these by high-resolution two-dimensional polyacrylamide gel electrophoresis.
METHODS
Four patients fulfilling the diagnostic criteria of BernardSoulier syndrome were studied. All four had experienced bleeding episodes and had increased bleeding times but have led reasonably normal lives since being under medical control. Patient V.S. (female, 28 yr old) from Switzerland had a bleeding time slightly longer than normal of 8 min (normals 1.5-6 min) and a decreased platelet count of 39,000-72,000/ul. The Factor VIII complex components were normal or increased, VIII:C, 100%; VIIIR:WF, 100%; VIIIR:Ag, 170%. Aggregation of platelets to ADP, collagen and epinephrine were normal. Platelets did not aggregate to ristocetin at 1.5 mg/ml. The peripheral blood smear showed typical giant platelets. Patient M.S. has been previously described (13) . Human blood platelets. The study was conducted according to the principles embodied in the Declaration of Helsinki. The isolation of a homogeneous preparation of Bernard-Soulier syndrome platelets was performed as previously described by Jamieson and Okumura (7), with minor modifications. Blood (70-80 ml) was drawn from informed, consenting patients or normal donors, collected in 10-ml tubes containing 1.4 ml acid-citrate-dextrose, 10 mM EDTA anticoagulant, and allowed to sediment (tubes tilted at an angle of 450, at room temperature (20°C), for 4 h. The platelet-rich plasma was then gently removed and diluted with an equal volume of Hanks' buffered saline containing 10 mM EDTA and no calcium or magnesium. The diluted platelet-rich plasma (5 ml) was then layered on top of 4 ml of Ficoll-Paque (Pharmacia Fine Chemicals, Uppsala, Sweden) in 10 ml plastic or siliconized glass tubes and centrifuged at 800 g for 10 min. Erythrocytes and granulocytes sedimented to the bottom of the tube, while platelets and contaminating lymphocytes were present as a narrow band at the interface.
The interface was removed, mixed with 0.012 M sodium citrate, 0.03 M glucose, 0.12 M NaCl pH 6.5 containing 10 mM EDTA to a volume of 8 ml and centrifuged at 80 g for 5 min. Supernatant and pellet were examined by phase-contrast microscopy or by bright field using a differential Wright stain. The supernatant was then centrifuged repeatedly at 100 g for 5 min, discarding the pellets until a homogeneous platelet population was obtained.
Labeling. Platelets from each Bernard-Soulier syndrome patient and a healthy donor were immediately washed after isolation and were labeled in parallel by lactoperoxidasecatalyzed iodination, periodate plus NaB3H4 or neuraminidase, galactose oxidase plus NaB3H4 as previously described (8, 13) . Isoelectric focusing and SDS-polyacrylamide gel electrophoresis (5-20% acrylamide linear gradient gels) were carried out as described (17) . After fixing, the gels containing 125I-labeled proteins were washed under running water for 1 (19) .
Incubation of labeled normal platelets in Bernard-Soulier or normal blood. Platelets from two normal donors with the same blood group (Al Rh+) as the Bernard-Soulier patients (E.H. and F.S.) were isolated, washed, and surface-labeled by the neuraminidase, galactose oxidase plus NaB3H4 or periodate plus NaB3H4 methods. The pellets of labeled platelets were resuspended in platelet poor plasma (3 ml), to which 7 ml of whole blood was added (total volume 10 ml, platelets adjusted to 250,000/,Ml). The platelet poor plasma and whole blood were from the Bernard-Soulier syndrome patients or from the normal donors. The labeled normal platelets resuspended either in Bernard-Soulier patient blood or in blood from the same donor were incubated for 30 min at 370C, then isolated and washed twice in 0.01 M Tris, 0.005 M EDTA, 0.154 M NaCl, pH 7.4 buffer before solubilization in SDS for SDS-polyacrylamide gel electrophoresis. Labeled normal platelet samples from the two donors were also directly solubilized for gel electrophoresis without incubation in blood.
Immunoprecipitation was carried out by the method of Kessler (20) water. The tubes containing the sediments were immersed in an ultrasonic bath (Branson Sonic Power Co. Danbury, CT) for 3 min, then treated at 100°C for 2 min, and finally centrifuged for 10 min at 6,000 g. The supernatants were analyzed directly by polyacrylamide gel electrophoresis (17) followed by fluorography (19) . Identification of the thrombin-cleavable glycoprotein (GPV).' Platelets (10') surface-labeled by either the periodate/NaB3H4 or neuraminidase/galactose oxidase/NaB3H4 methods, suspended in phosphate-buffered saline, pH 7.4, were divided into two aliquots. One was treated with thrombin (1 U) for 10 min at 37°C, whereas the control was treated similarly without addition of thrombin. The samples were centrifuged at 1,100 g for 15 min, the supernatants were lyophilized and redissolved in 100 gl water and both the supernatants and the pellets were prepared for gel electrophoresis (17) followed by fluorography (19) .
RESULTS
Periodate + NaB3H4 labeling. The platelets from patients V.S. and F.S. showed distinct differences from normal ( Fig. 1) . GPIb (clearly identifiable by changes in molecular weight between unreduced and reduced in normals) was absent or present only in trace amounts. GPV (identified by its absence or decrease in thrombin-treated normal platelets, see also section on neuraminidase + galactose oxidase + NaB3H4 labeling) could either not be detected (patient V.S.) or was detectable at a very low level (patient F.S.). In addition, two other low molecular weight glycoproteins, clearly visible in normals, could not be detected. One of these had an apparent molecular wt of 22,000 and an apparent isoelectric point (pI) of 7.2-7.5 and could be identified as the f3-subunit of GPIb by various criteria: This glycoprotein was not present or present only in trace amounts detectable after long exposure times if normal platelets were analyzed in the unreduced state. It is precipitated along with the a-chain of GPIb by an antibody against glycocalicin (Fig. 2a) and can be demonstrated to split off from GPIb when GPIb purified by lectin affinity chromatography on peanut agglutinin was analyzed by two-dimensional polyacrylamide gel electrophoresis in the reduced state. The second glycoprotein that could not be detected had a molecular mass of -17,000 daltons and a pl of 5.8-6.5, and was present in normal platelets in both the reduced and the unreduced states in the same position. Even All of the glycoproteins not detected with patients V.S. and F.S. could be seen with the platelets from patient E.H. (Fig. Id) . However, they were clearly present in lower amounts than normal. Because the xray films used were flashed to increase their sensitivity, the response to light is approximately linear (19) , and densitometry of the spots on the film can be used to estimate the quantity of the component present on the platelet surface. Although GPIba cannot be easily assessed in this manner because of the proximity of other glycoproteins and also the heterogeneity of GPIba in the isoelectric focusing dimension, it was possible to shown). Differences in the GPIb region have already been described with this patient (13) . One of the normal controls showed a different pattern for GP175.8-6-5 (in the reduced state) compared with other single normals or to normal pool platelets. Instead of the usual two major spots and one minor, four spots were seen with the additional spots more acidic than normal (Fig. lb) .
Neuraminidase + galactose oxidase + NaB3H4 labeling. The platelets from patients V.S. and F.S. again showed marked differences from normal (Fig. 3) . GPIba was absent or present only in trace amounts. The same two low molecular weight glycoproteins were absent as with periodate/NaB3H4 labeling. In normals the position of GPIb,B was not greatly affected by neuraminidase but GP175865 was shifted to a more basic pI, now running nearer to GPIb# at pI 6.1-6.8.
The thrombin-cleavable glycoprotein termed GPV or SP85 (23) (24) (25) was not detectable. This glycoprotein was identified by thrombin treatment of surface-labeled normal platelets. Fig. 4 shows fluorograms of two-dimensional gels of surface-labeled normal platelets, normal platelets after treatment with thrombin and the supernatant after treatment with thrombin. The only glycoprotein affected is GPV, which is removed from the platelet surface. At the same time a smaller glycopeptide, which is a fragment of GPV termed GPVf1 (26) In all these patients several spots could be seen in the GPV region, after long exposure times. However, there were no differences from normal and GPV could not be definitively identified in normals by thrombin treatment presumably because it is very poorly labeled by iodination. The lower molecular mass (<40,000 daltons) regions also showed no difference from normal. Incubation of labeled normal platelets in BernardSoulier or normal blood. Normal platelets were labeled by either the periodate/NaB3H4 or the neuraminidase/galactose oxidase/Na3H4 method and then The only labeled component present is the hydrophilic fragment of GPV, termed GPVfl (26) . The cleavage of GPV by thrombin was similar with periodate/NaB3H4-labeled platelets.
incubated in either normal blood or Bernard-Soulier blood. After reisolation and gel electrophoresis followed by fluorography the results of the different treatments were compared. Fig. 5 shows two-dimensional separations of periodate platelets + NaB3H4 labeled in the reduced state. As can be clearly seen there are no obvious differences between the labeled normal platelets (Fig. 5a) , the labeled normal platelets incubated in normal blood (Fig. 5b) , and the labeled normal platelets incubated in Bernard-Soulier blood (Fig. 5c) .
In particular there were no changes in GPV or in GP1758-65. Densitometry of one-dimensional gels (not shown) also showed no difference between the variously treated platelets.
DISCUSSION
The Bernard-Soulier syndrome platelets examined in the present study showed the classic membrane glycoprotein defect of this disorder, a deficiency in GP Ib, which has been described by several authors using various techniques (8) (9) (10) (11) (12) (13) (14) . In the majority of cases described in the literature GPIb appears to be totally absent; however in some cases it appears to be present in reduced amounts. (6, 7) that were ascribed to the absence of GPIb, which is known to bind thrombin and has been claimed to be the highaffinity thrombin binding site on platelets (6, 28) . In one of these reports both the high affinity and the low affinity binding sites were reduced (7) .
Considerable controversy exists on the nature of the platelet thrombin receptor and two possible candidates have been proposed. One of these is GPIb/glycocalicin, which has been reported to have a high affinity for thrombin (28) . However, a-thrombin inactivated with reagents such as diisopropyl fluorophosphate or phenyl methyl sulphonyl fluoride does not activate platelets though it binds with the same affinity as untreated thrombin (29) . This result led others to seek for a receptor that was cleaved by thrombin and the evidence points to this being GPV (SP 85) (23, 24) .
The changes in GPV in Bernard-Soulier syndrome observed here might be a direct consequence of the deficiency of GPIb if this indeed acts as a high-affinity receptor for thrombin. In circulation the Bernard-Soulier platelets would be exposed to low amounts of thrombin and in the absence of the high-affinity receptor this would bind to and cleave GPV. If this took place at a sufficiently low concentration it would probably not activate the platelets but their ability to respond to larger amounts of thrombin would gradually be reduced. It is, of course, not yet possible to distinguish whether GPV is affected in its entirety or only its carbohydrate moiety. In the latter case the changes in thrombin-induced aggregation in Bernard-Soulier platelets might be caused by changes in conformation in GPV as a result of the defective glycosylation.
Since it is known that GPV is a peripheral platelet glycoprotein that can be removed by changes in ionic strength (26) and in view of the transition that occurs in Bernard-Soulier syndrome platelets when they become "giant-sized" the most likely possibility is that GPV is lost from Bernard-Soulier syndrome platelets during the extensive washing that is part of the surface-labeling methods. This would also imply that GPIb and GPV are associated on the platelet surface and that GPIb stabilizes the association of GPV with the membrane, which would fit in well with the idea of coupling of binding of thrombin to signal generation via cleavage of a receptor (30) .
One of the diagnostic characteristics of BernardSoulier syndrome is the tendency of the platelets to become giant on undergoing "shape-change." These platelets are apparently normal-sized in circulation unlike those in May-Hegglin's disease (31) . The role that the membrane glycoproteins play in this phenomenon is still unclear but the deficiency or absence of GPIb with its two-chain structure and of GP1758-65, which is probably also an integral membrane glycoprotein, must have a profound influence on the structure of the membrane.
Thus, although the absence or strong depletion of both subunits of GP Ib remains the main biochemical characteristic of Bernard-Soulier syndrome platelets there are other changes in the surface glycoproteins, particularly the absence or strong depletion of GP175.".5 with carbohydrate-labeling methods, which may be equally responsible for some of the peculiarities that characterize Bernard-Soulier syndrome platelets.
